These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 16945568

  • 1. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.
    van Horssen R, Eggermont AM, ten Hagen TL.
    Cytokine Growth Factor Rev; 2006 Oct; 17(5):339-48. PubMed ID: 16945568
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells.
    Tandle AT, Mazzanti C, Alexander HR, Roberts DD, Libutti SK.
    Cytokine; 2005 Jun 21; 30(6):347-58. PubMed ID: 15935955
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apoptosis induced by a corneal-endothelium-derived cytokine.
    Liu SH, Gottsch JD.
    Invest Ophthalmol Vis Sci; 1999 Dec 21; 40(13):3152-9. PubMed ID: 10586937
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury.
    Nührenberg TG, Langwieser N, Schwarz JB, Hou Y, Frank P, Sorge F, Matschurat S, Seidl S, Kastrati A, Schömig A, Clauss MA, Zohlnhöfer D.
    Cardiovasc Res; 2008 Feb 01; 77(3):580-9. PubMed ID: 18029408
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N, Schwarz MA, Schwarz RE.
    Cancer Chemother Pharmacol; 2011 Sep 01; 68(3):571-82. PubMed ID: 21110024
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light protein.
    Xu H, Malinin NL, Awasthi N, Schwarz RE, Schwarz MA.
    J Biol Chem; 2015 Apr 10; 290(15):9753-66. PubMed ID: 25724651
    [Abstract] [Full Text] [Related]

  • 20. Heparan sulfate regulates the antiangiogenic activity of endothelial monocyte-activating polypeptide-II at acidic pH.
    Chang SY, Ko HJ, Heo TH, Kang CY.
    Mol Pharmacol; 2005 May 10; 67(5):1534-43. PubMed ID: 15710745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.